Clinical trials: Anti-NMDAR Encephalitis
Autoimmune Encephalitis, Encephalitis
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and…
- Trial name
- ExTINGUISH (NCT04372615)
- Testing
- Inebilizumab
- Where
- 39 sites in United States, Netherlands and 1 more
- Volunteers
- 116 people
- Sponsor
- University of Utah